Pharmaceuticals, Biotechnology and Life Sciences
First gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype now…
NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces the clearance…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced…
Bristol-Myers Squibb study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the…
Novartis has ended third quarter 2019 with reported net income of $2.0 billion, which as an 8% increase, driven by higher operating income and higher income from associated companies, saying in the press release Tuesday that its EPS was USD 0.90 (+11%, +14% cc), growing faster than net income driven by lower weighted average number of shares outstanding.
Bicycle is going to collaborate with ODDI, an organization with deep expertise in the molecular pathology of Alzheimer’s disease and…
Takeda got exclusive global license for investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle designed to induce tolerance to gluten in…
AstraZeneca on Monday said that that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Seattle Genetics’s trial of tucatinib in HER2-positive breast cancer has met primary and secondary endpoints, showing that the addition of tucatinib was superior to trastuzumab and capecitabine alone, and the company is planning NDA Submission to U.S. FDA for first quarter of 2020.
Vertex Pharmaceuticals received FDA’s approval for Trikafta (elexacaftor/tezacaftor/ivacaftor), for treating cystic fibrosis in patients older than 12, who have at…